Ionis Pharmaceuticals Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 9, 2026 results vs estimates
Ionis Pharmaceuticals Inc Forecast
Ionis Pharmaceuticals Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 37.2% a year, a typical one-standard-deviation range is 42.06–46.72 over a week, 39.62–49.16 over a month and 27.87–60.91 over a year. (Signals as of 1 Nov 2026.)
Ionis Pharmaceuticals Inc Price Chart
Ionis Pharmaceuticals Inc Factors
YoY −39.2%
YoY −5.3%
YoY −32.9%
YoY +237.6%
YoY +253.2%
YoY −39.7%
YoY −135.8%
YoY +94.6%
YoY +93.0%
YoY +239.1%
YoY +126.9%
YoY −25.0%
YoY −66.6%
Ionis Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow
Ionis Pharmaceuticals Inc reported revenue of $944.0m and net income of -$381.0m in FY2025, the year ended 31 December 2025 — revenue up 33.9% and net income up 16.1% on the prior year. Free cash flow was -$320.0m. These figures are as reported in the filings, not restated: 36 fiscal years and 147 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 944.0 | 705.1 | 787.6 | 587.4 | 810.5 |
| Cost of revenue | 16.0 | 11.2 | 9.1 | 14.1 | 10.8 |
| Gross profit | 928.0 | 693.9 | 778.5 | 573.3 | 799.6 |
| Research & development | 916.0 | 901.5 | 899.6 | 833.0 | 643.0 |
| Selling, general & admin. | 393.9 | 267.5 | 232.6 | 150.3 | — |
| Operating income | -382.0 | -475.1 | -353.7 | -410.2 | -30.2 |
| EBITDA | -284.3 | -353.7 | -235.9 | -227.8 | -5.2 |
| Interest expense | 90.5 | 90.5 | 81.5 | 8.1 | 9.3 |
| Pre-tax income | -380.0 | -460.1 | -334.0 | -258.0 | -29.1 |
| Income tax | 1.0 | -6.2 | 32.3 | 11.7 | -0.6 |
| Net income | -381.0 | -453.9 | -366.3 | -269.7 | -28.6 |
Download Ionis Pharmaceuticals Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.IONS.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Ionis Pharmaceuticals Inc
Explore MacroFinance macro & markets research and analysis.
Ionis Pharmaceuticals Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Ionis Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Ionis Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Ionis Pharmaceuticals Inc (United States)
Ionis Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Ionis Pharmaceuticals Inc?
What is the latest Ionis Pharmaceuticals Inc price?
Is Ionis Pharmaceuticals Inc in an uptrend?
How volatile is Ionis Pharmaceuticals Inc?
What factors affect Ionis Pharmaceuticals Inc?
Which trading strategies trade Ionis Pharmaceuticals Inc?
How are Ionis Pharmaceuticals Inc returns analysed?
Where can I download free Ionis Pharmaceuticals Inc historical data?
Free Ionis Pharmaceuticals Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Ionis Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.IONS.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 26.58 |
| 2026-11-19 | 27.22 |
| 2026-11-18 | 27.39 |
| 2026-11-17 | 26.96 |
| 2026-11-16 | 28.01 |
| 2026-11-13 | 29.06 |
| 2026-11-12 | 27.31 |
| 2026-11-11 | 28.33 |
| 2026-11-10 | 28.19 |
| 2026-11-09 | 31 |
About this stock
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.